Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.

Fremd, Carlo; Jaeger, Dirk; Schneeweiss, Andreas

Fremd, Carlo; Jaeger, Dirk; Schneeweiss, Andreas.

Fremd C; a National Center for Tumor Diseases, Department of Medical Oncology , University of Heidelberg , Heidelberg , Germany.
Jaeger D; a National Center for Tumor Diseases, Department of Medical Oncology , University of Heidelberg , Heidelberg , Germany.
Schneeweiss A; a National Center for Tumor Diseases, Department of Medical Oncology , University of Heidelberg , Heidelberg , Germany.

Expert Rev Anticancer Ther ; 19(1): 29-42, 2019 01.

Article en En | MEDLINE | ID: mdl-30351981

Asunto(s)

Antineoplásicos/farmacología; Terapia Molecular Dirigida; Neoplasias de la Mama Triple Negativas/tratamiento farmacológico; Animales; Femenino; Humanos; Inmunoterapia/métodos; Inhibidores de Poli(ADP-Ribosa) Polimerasas/farmacología; Neoplasias de la Mama Triple Negativas/inmunología; Neoplasias de la Mama Triple Negativas/patología

Palabras clave

BRCA; PARP; PD-1; PD-L1; Triple-negative breast cancer; immune checkpoint blockade; pembrolizumab; resistance; targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Terapia Molecular Dirigida / Neoplasias de la Mama Triple Negativas / Antineoplásicos Límite: Animals / Female / Humans Idioma: En Año: 2019 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google